



## Preferred Drug List

### NEW DRUG REVIEW

**Proprietary Name:** Intelence™

**Common Name:** Etravirine

**PDL Category:** Antiretrovirals- RTI-Non-Nucleoside Analogues

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Rescriptor®	Recommended
Sustiva®	Recommended
Viramune®	Recommended

#### Summary

**Indications and Usage:** Non-Nucleoside reverse transcriptase inhibitor (NNRTI) for use in combination therapy in treatment experienced adults who have HIV-1 infection resistant to an NNRTI and other antiretroviral agents.<sup>1</sup>

**Mechanism of Action:** Binds directly to reverse transcriptase and blocks DNA polymerase by disrupting the enzyme's catalytic site.<sup>1</sup>

**Dosage Forms:** Tablets: 100mg

**Recommended Dosage:** 200mg twice daily following a meal.<sup>1</sup>

**Common Adverse Drug Reactions:** Rash, nausea, peripheral neuropathy, and hypertension.<sup>1</sup>

**Contraindications:** None<sup>1</sup>

**Manufacturer:** Janssen Cilag for Tibotec, Inc.

**Analysis:** Intelence™ is a new NNRTI indicated for the treatment of HIV-1 infection, in combination with other antiretrovirals, in adult patients with previous NNRTI resistant virus. In the trials used to gain FDA approval, Intelence™ was compared to placebo, each including a background regimen, with the primary endpoint of an undetectable viral load. The Intelence™ arm achieved the endpoint at 59.8% compared to placebo at 40.2%. Intelence is the first NNRTI to show antiviral activity in patients with previous resistance to a NNRTI and other antiviral agents, and thus was granted accelerated FDA approval. Intelence use has not been studied in pediatric patients and treatment-naïve adult patients. Recommended alternatives appear on the Preferred Drug List, which have pediatric indications and are more cost effective. Therefore, it is recommended that Intelence™ be added to the Preferred Drug List as a non-recommended drug.

**IME Recommendation:**

<input type="checkbox"/> Preferred Drug	<input type="checkbox"/> Recommended Drug
<input type="checkbox"/> Non-Preferred Drug	<input checked="" type="checkbox"/> Non-Recommended Drug
<input type="checkbox"/> Preferred Drug with Conditions	

1. Intelence™ [package insert]. Raritan, NJ: Tibotec Therapeutics; 2009.